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pcDNA3-HERG by site-directed mutagenesis, expressed by transient transfection of 
human embryonic kidney ceils, and characterized electrophysiologically. 
Results: 8 of the 93 cases of SIDS possessed 4 novel nonsynonymous ingle nucteotide 
polymorphisms (SNPs, amino acid variants). However, 3 of the variants were identified in 
ethnic-matched controls. A putative SIDS-causing HERG mutation was found in exon 4 
from a 6-month-old Caucasian male. This N-terminal mutation was not present in 200 
alleles from Caucasian controls. Functionally, this mutation results in significantly 
decreased levels of whole cell current compared to wild type. 
Conclusions: Approximately 1% of this prospective, population-based cohort of SIDS 
cases had an identifiable HERG channel defect. This study implicates cardiac eotassium 
channels in SIDS for the first time. In addition, the study illustrates the importance of eth- 
nic-matched controls to avoid the erroneous assignment of novel nonsynonymous SNPs 
as putative BIDS-causing mutations. 
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857-2 Effect of Phenylephrine Provocation on Dispersion of 
Repolarization in Congenital Long QT Syndrome 
Anant Khositseth, Jan Nemec, Joseph Hejiik, Win K. Shen, Michael J. Ackerman, Mayo 
Clinic, Rochester, Minnesota. 
Background: Syncope or sudden cardiac arrest is associated with sympathetic stimula- 
tion in LQT1. LQT2 and LQT3 patients are more susceptible to arrhythmias at lower 
heart rates. Spatial dispersion of repolarization is estimated by QT dispersion (QTd = 
QTmax - QTmin) whereas transmurel dispersion of repolarization (TDR) is estimated by 
the interval from T peak to T end (Tp-e). This study compares the effect of phenylephrine 
on QTd and TDR in genotyped long QT syndrome (LQTS) to control (C). 
Methods: 17 patients (12 F, 26,9 + 11.6 years) with LQT1, 15 patients (8 F, 26,7 + 12.9 
years) with LOT2/3, and 18 age- and gender- matched normal controls (10 F, 26.3 + 12.3 
years) were given a phenylephrine bolus intravenously at 2 mcg/kg. At baseline and at 
peak phenylephrine ffect, BP, QT, RR, Bazett's QT c, precordial QTd, and Tp-e intervals 
were determined blinded to the patient's clinical and genotype status. 
Results: Baseline QT intervals (482!-45 ms and 542+76 vs, 414±27) and OTc (476+26 
ms and 516+46 vs. 422+28) were significantly longer in LQT1 and LQT2/3 compared to 
control (p < 0.0001). Baseline QTd and Tp-e in LQT2/3 were greater than both LQT1 and 
control: QTd = 84+29 ms (LQT2/3), 53+25 (LQT1), 44+15 (C), p < 0.0001 and Tp-e = 
121:tr.28 ms (LQT2/3), 99+21 (LOT1), and 90+11 (C), p < 0.0003. Phenylephrine signifi- 
cantly increased blood pressure and slowed heart rate in all groups as expected. Phe- 
nylephrine exerted no significant effect on either QTd or Tp-e in all groups, Subgroup 
analysis of svmctomatic LOT1 (n=5) and symptomatic LQT2/3 (n=4) demonstrated a sig- 
nificant change in TDR following phenylephrine. In symptomatic LQT1, Tp-e decreased 
by 9 + 27 ms whereas Tp-e increased by 16 + 22 in symptomatic LOT2/3, p < 0.02). Phe- 
nylephrine tended to impact QTd differentially as well between symptomatic LOT1 and 
symptomatic LQT2/3 (-16 + 11 vs. 4 + 12). 
Conclusions: Phenylephrine-induced bredycardia decreased TDR in symptomatic 
LOT1 but increased TDR in symptomatic LOT2/3. The observed effects of phenylephrine 
are consistent with the protective effect of beta-bleeker therapy in LQT1 and the 
increased arrhythmogenicity noted during non-exertional states in LQT2/3. 
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857-3 The Mechanism of Ventricular Arrhythmia on a Canine 
Isolated Blood-Perfused Brugada Syndrome Model 
Masaomi Kimura, Takao Kobayashi, Shingen Ohweda, Shingo Saseki, Tomonori 
Igarashi, Atsushi Iwasa, Shigeru Motomura, Ken Okumura, Hirosaki Universi~ Hirosaki, 
Japan. 
Background: Brugada syndrome is characterized by ST elevation in the right precordial 
leads and high incidence of ventricular arrhythmlas (VA). Phase 2 reentry was suggested 
as a mechanism for VA in the canine right ventricular (RV) preparation perfused with 
Tyrode solution. 
Methods: In an isolated canine RV preparation cross-circulated with arterial blood of the 
support dog (n=8), we simultaneously recorded a transmural ECG and 96 bipolar electro- 
grams using two rectangular plaque electrodes (35x30mm, each contained 48 elec- 
trodes) attached to the endocardial (ENDO) and epicardial aspects (EPI) of the 
preparation. Each preparation was paced at a cycle length of 800 msec. 
Results: Saddle-back and coved types of ST elevation were observed after administra- 
tion of a low (<51Jmol/L) and high doses (>8p.mol/L) of pilsicainide (a pure Na ÷ channel 
blocker), respectively, to the pertusion blood in addition to pinacidU (201Jmol/L). In 4 prep- 
arations, polymorphic ventricular tachycardia (V'I') developed after an extrasystole spon- 
taneously occurring from EPI at the middle of repelarization phase of the preceding beat. 
Activation map during the initial phase of v'r revealed unstable reentry between ENDO 
and EPI with migrating functional block (Figure). 
Conclusion: Thus, VT in this "Brugada syndrome model" was initiated by phase 2 reen- 
try in EPI and subsequent unstable reentry between ENDO and EPI. 
; ; .~ .n l  ECG ~_.NDO EP I  
JACC March 6, 2002 
11:15 a.m. 
857-4 Incidence of Patients at High Risk of Sudden Death 
Among Patients Referred for  the Suspicion of a 
Brugada-Syndrome: A Prospective Study in 35 
Consecutive Patients With Brugada-Like ECG Changes 
Constanze M. Echternach, Martin Borggrefe, Susanne Spahl, Ayse Bilbal, Michael 
Junker, Juergen Kuschyk, Tim S0selbeck, Karl K. Haase, Christian Wolpert, DepL of 
Cardiology, University Clinic Mannheim, University of Heidelberg, Mannheim, German~ 
Background: Since the Brugeda-like ECG changes are now familiar to a larger number of 
physicians, referral to specialized arrhythmia clinics for further diagnosis and risk stratifi- 
cation of patients presenting with an abnormal ECG in V1 to V3 is increasing. However, 
since the patients are very heterogenous with respect to family history, symptoms and 
age and sex, decision finding especially in asymptomatic patients remains still very diffi- 
cult, The aim of the study was to assess prospectively the incidence of patients with Bru- 
geda-like ECG changes who are at high risk according to the consensus in consecutive 
patients. Patients and methods: A total of 35 patients were referred to our arrhythmia unit 
for abnormal ECG in leads V1 to V3, 19/35 were of male sex. 12 patients had a history of 
syncope, 4 patients palpitations, 3 patients had aborted sudden death, two patients a car 
accident with non-observed loss of consciousness and 5 patients a positive family history 
of sudden death. All patients underwent ajmaline test, 6 patients additional flecainide 
test, 15 patients electrophysiological study. Results: Ajmaline test was positive in 12/35 
patients. In the 6 patients in whom ajmaUns test was positive, flecainide test was positive 
as well. 3/15 patients with a positive ajmaline test had inducible polymorphic VT or VF in 
the programmed stimulation. All of these patients had syncope and/or a positive family 
history. All three patients were implanted a csrdioverter-defibrillator. Device data storage 
did not reveal any v r  or VF events during a mean follow-up of 5 months. Conclusions: 1. 
The incidence of patients at high risk of sudden death among consecutive patients 
referred for Brugada-like changes in the surface ECG is 3/35 in the present observation. 
2. This justifies a full work up including invasive electrophysiological testing. 3. All 
patients who were inducible had either a positive family history or syncope. 
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857-5 Clinical Noninvasive- lnvasive Evaluation and Five-Year 
Follow-Up in Patients With the Brugads Syndrome: A 
Prospective Excel-Access Database 
Franco NaccareHa, Giovannina Lepera, Stafano Maranga, Cardiologia Azienda USL 
Citt~ di Bologna, Bologna, Italy, Cardiology Herman Hospital Houston, Houston, Texas. 
PURPOSE. The Brugada Sindrome (BS) is characterized by clinical, ECG and pheno- 
type differences, the genetic characterization of which has not been completely per- 
formed. Furthermore, prognostic differences have been described in subjects suffering 
from a previous cardiac arrest (PCA), ECG abnormalities in rest condition (ECG R) or 
after flecainide infusion (ECG F), inducibility of major ventricular arrhythmias (IND.VA) at 
PES, syncopal episodes (SE) without evidence of VA. 
METHODS. To this purpose, we evaluated 64 subjects, belonging to nine different fami- 
lies suffering from BS, 7/9 with a proband member affected by PCA, 1/9 with VT, and the 
last one without IND VA. Patients with PCA were treated with an ICD, one patient with VT 
received Amiodarone (A). Patients with dubious ECG received Flecainide 1.5 (1-2) mg/ 
Kg infusion (FT). Results are reported in the following table, according to different 
aspects and symptoms of the disease, considering recurrences of CA, syncopal epi- 
sodes (SE) in a follow up (FUP) of 42 ± 12 months. 
CONCLUSIONS. 1) Different clinical evolutions over time can be observed in patients 
with the Brugada Syndrome and specific clinical features to begin with. 2) Mainly patients 
with CA and SE show the worst prognosis. 3) Normal ECG in asymptomatic patients with 
a negative FT are associated with a benign prognosis. 4) The role of FT and IND. VA at 
PES should be furtherly evaluated. 
OBS. RESULTS FUP CA 
PCA 7/9 7/7 (ICD) 2/7 2/7 
VT 1/9 1/1 (IND. VA) 1/1 0/1 
NO VTNF 1/9 0/1 (IND. VA) 1/t 0/1 
SE 9/64 3/9 (IND. VA) 3/3 2/3 
ECG R DUBIOUS 7/64 7/7 (+ FT) 
(IND VA) 3/7 (IND. VA) 3/3 1/3 
ECG R ATYPICAL 18/64 2/18 (+ FT) 
(non IND VA) 0/2 (IND. VA) 0/2 
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857-6 Ajmaline Versus Procainamide Challenge Test in the 
Diagnosis of Sudden Unexplained Death or Brugada 
Syndrome 
Gumoanart Veerakul, Lertlak Chaothawee, Banharn Koanantakul, Koonlawee 
Nademanse, Cardiovascular Research Center, Bhumibol Adutyadej Hospital, RTAF, 
Bangkok, Thailand, Pacific Rim Electrophysiology Research Institute, Inglewood, 
California. 
Sudden Unexplained Death Syndrome (SUDS), is characterized by an abnormal ECG 
with ST-elevation in V1-V3 and sudden death, similar to that seen in the Brugeda syn- 
drome. But the ECG marker waxes and wanes and may be normal at the initial presenta- 
